US4771130A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Target-entrapped drugs
Assignee: Individual
•
Filing: 1984-02-17
•
Granted: 1988-09-13
•
Expires: 2004-02-17
Abstract
Abstract A target-entrapped drug comprising three chemically joined components (1) the active drug component; (2) a linking chain; and (3) an activatable group; the activatable group on exposure of the drug to activation liberating components (1) and (2) so that the drug component (1) is bound to a selected target site through the linking chain (2). The drug is administered and then activated by exposure to electromagnetic radiation or other energy such as thermal energy at the anatomic target site.
Inventors
- 👤 William Cohen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:02
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0028
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
101 words
A drug composition comprising three chemically joined components: (1) a therapeutically active drug component which acts at suitable receptor sites available for covalent bonding; (2) a therapeutically-acceptable component which is activatable by an external energy source selected from the group consisting of visible or ultraviolet light or X-ray to covalently bond the drug component(s) to the selected receptor site; and (3) a therapeutically-acceptable linking component connecting (1) and (2), wherein upon administration of the drug composition and exposure to said external energy source, the therapeutically active drug component is covalently bound to said receptor sites through the components (2) and (3).
Claim 2
Dependent Claim
101 words
A drug composition comprising three chemically joined components: (1) a therapeutically active drug component which acts at suitable receptor sites available for covalent bonding; (2) a therapeutically-acceptable component which is activatable by an external energy source selected from the group consisting of visible or ultraviolet light or X-ray to covalently bond the drug component(s) to the selected receptor site; and (3) a therapeutically-acceptable linking component connecting (1) and (2), wherein upon administration of the drug composition and exposure to said external energy source, the therapeutically active drug component is covalently bound to said receptor sites through the components (2) and (3).
Claim 3
Dependent Claim
51 words
A composition according to claim 1 wherein component (1) is an enzyme inhibitor; the linking component (3) comprises an inert polymethylene diamine chain and component (2) includes an azide group which is activatable by said external energy to covalently bind the inhibitor to a receptor site through the linking component (3).
Claim 4
Dependent Claim
21 words
A drug composition according to claim 1 which comprises a visible or ultra-violet light or X-ray activatable azide-substituted aldose reductase inhibitor.
Claim 5
Dependent Claim
12 words
A drug composition according to claim 3 which is an axide-substituted quercitrin.
Claim 6
Dependent Claim
10 words
A drug composition according to claim 4 which is N-(2-nitro-4-azidophenyl)hexylenediamine-N-(2'-O-quercitrin).
Claim 7
Dependent Claim
22 words
A pharmaceutical composition in dosage unit form comprising an effective amount of a compound according to claim 1, and a pharmaceutically-acceptable carrier.
References Cited (Backward Citations)
US3346559A
Cited
US4021546A
Cited
US4328204A
Cited
US4263428A
Cited
US4419348A
Cited
US4671958A
Cited
US4496548A
Cited
US4474751A
Cited
US4474753A
Cited
US4478822A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-13 | 1992-03-14 | 1992-09-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-13 | 1996-03-14 | 1996-09-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-13 | 2000-03-14 | 2000-09-13 | $7700.00 | Window Closed / Lapsed |